AJA University of Medical Sciences, Tehran 1411718541, Iran.
PPAR Res. 2013;2013:358074. doi: 10.1155/2013/358074. Epub 2013 Apr 18.
The present trial aimed to investigate the effects of pioglitazone on the serum level of asymmetric dimethylarginine (ADMA), a marker of endothelial function, and some indices of inflammation and glucose and lipid metabolism in nondiabetic metabolic syndrome patients. 104 eligible participants (57% female; age between 20 and 70) were enrolled in a double-blind placebo-controlled trial and were randomized to receive either pioglitazone (uptitrated to 30 mg/day) or matching placebo for 24 weeks. Participants were clinically examined and a blood sample was obtained at baseline and at the end of the trial. Pioglitazone significantly improved C-reactive protein level irrespective of changes in insulin sensitivity. Compared with the placebo group, alanine and aspartate transaminases were decreased and high-density lipoprotein cholesterol was increased after treatment with pioglitazone. A considerably greater weight gain was also recorded in the intervention group. We failed to observe any significant changes in serum ADMA in either group and between groups with and without adjustment for age, sex, and components of the metabolic syndrome. In a nutshell, pioglitazone seems to have positive effects on lipid profile, liver transaminases, and systemic inflammation. However, its previously demonstrated endothelial function-improving properties do not seem to be mediated by ADMA.
本研究旨在探讨吡格列酮对非糖尿病代谢综合征患者血清不对称二甲基精氨酸（ADMA）水平、炎症和葡萄糖及脂代谢部分指标的影响。104 名符合条件的参与者（57%为女性；年龄在 20-70 岁之间）被纳入一项双盲安慰剂对照试验，并随机分为吡格列酮（最大剂量为 30mg/天）组或匹配的安慰剂组，接受治疗 24 周。参与者接受临床检查，并在基线和试验结束时采集血样。吡格列酮可显著改善 C 反应蛋白水平，而不论胰岛素敏感性是否发生变化。与安慰剂组相比，吡格列酮治疗后丙氨酸氨基转移酶和天冬氨酸氨基转移酶降低，高密度脂蛋白胆固醇升高。干预组的体重也显著增加。我们未观察到两组患者血清 ADMA 有任何显著变化，也未观察到在调整年龄、性别和代谢综合征成分后两组间有任何显著变化。简而言之，吡格列酮似乎对脂代谢谱、肝转氨酶和全身炎症具有积极影响。然而，其先前显示的改善内皮功能的作用似乎并非通过 ADMA 介导。
